Form 4: Acadia Pharmaceuticals Officer James Kihara Reports Stock Transactions
SEC Form 4 Filing
James Kihara, Principal Accounting Officer of Acadia Pharmaceuticals, reports the vesting of restricted stock units and subsequent sale of shares to cover withholding taxes.
Summary
- James Kihara, Principal Accounting Officer at Acadia Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
- On February 23, 2024, 840 shares of common stock were acquired through the vesting of restricted stock units.
- On February 26, 2024, 474 shares were sold at $24.67 per share to cover withholding taxes related to the vesting of the restricted stock units.
- Following these transactions, Kihara directly owns 11,391 shares of Acadia Pharmaceuticals stock.
- The restricted stock units vest in four equal annual installments beginning February 23, 2022.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing stock transactions by an officer. It doesn't inherently convey positive or negative sentiment, as it's a routine disclosure.
Industry Context
Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge management's sentiment and confidence in the company's prospects.
Key Dates
| Date | Description |
|---|---|
| February 23, 2022 | Start date for the vesting of restricted stock units in four equal annual installments. |
| February 23, 2024 | Acquisition of 840 shares of common stock through vesting of restricted stock units. |
| February 26, 2024 | Sale of 474 shares at $24.67 per share to cover withholding taxes. |
| February 27, 2024 | Date of the Power of Attorney execution. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.